CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING

Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiti...

Full description

Bibliographic Details
Main Authors: I. A. Koroleva, M. V. Kopp, E. M. Lipaeva
Format: Article
Language:Russian
Published: Remedium Group LLC 2017-11-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/2175
Description
Summary:Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiting in patients with breast cancer receiving chemotherapy regimen AC.Materials and methods: 82 female patients with breast cancer received adjuvant chemotherapy regimen AC: doxorubicin 60 mg/ m2, cyclophosphamide 600 mg/m2  in day 1, each 21 day 4 cycle. Patients received an triple-therapy regimen (aprepitant 125 mg p.o. in day 1, 80 mg in days 2 and 3, ondansetron 8 mg i.v. in 1 day, dexamethasone 12 mg i.v.in 1 day, then to 8 mg/day p.o. in days 2–4)  for prevention of nausea and vomiting.Results: During the first cycle of chemotherapy in acute phase (0-24  hours from the start of chemotherapy) complete control of nausea and vomiting was achieved at 72 (87.8%) patients. During delayed phase (25-120 hours from the start of chemotherapy) complete control achieved at 56 (68.3%)patients . 57.3% of patients had complete control of nausea and vomiting during all 4 cycles.Conclusion: Adequate regimen for prevention of nausea and vomiting is combination of NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone. Triple-therapy regimen allows more than half of the patients undergo 4 cycles of AC without nausea and vomiting.
ISSN:2079-701X
2658-5790